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Background: Mesenchymal stem cells (MSCs) are increasingly used as therapeutic agents as well as research tools
in regenerative medicine. Development of technologies which allow storing and banking of MSC with minimal loss
of cell viability, differentiation capacity, and function is required for clinical and research applications.
Cryopreservation is the most effective way to preserve cells long term, but it involves potentially cytotoxic
compounds and processing steps. Here, we investigate the effect of decreasing dimethyl sulfoxide (DMSO)
concentrations in cryosolution by substituting with hydroxyethyl starch (HES) of different molecular weights using
different freezing rates. Post-thaw viability, phenotype and osteogenic differentiation capacity of MSCs were
analysed.
Results: The study confirms that, for rat MSC, cryopreservation effects need to be assessed some time after, rather
than immediately after thawing. MSCs cryopreserved with HES maintain their characteristic cell surface marker
expression as well as the osteogenic, adipogenic and chondrogenic differentiation potential. HES alone does not
provide sufficient cryoprotection for rat MSCs, but provides good cryoprotection in combination with DMSO,
permitting the DMSO content to be reduced to 5%. There are indications that such a combination would seem
useful not just for the clinical disadvantages of DMSO but also based on a tendency for reduced osteogenic
differentiation capacity of rat MSC cryopreserved with high DMSO concentration. HES molecular weight appears to
play only a minor role in its capacity to act as a cryopreservation solution for MSC. The use of a ‘straight freeze’
protocol is no less effective in maintaining post-thaw viability of MSC compared to controlled rate freezing methods.
Conclusion: A 5% DMSO / 5% HES solution cryopreservation solution using a ‘straight freeze’ approach can be
recommended for rat MSC.
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Mesenchymal stem cells (MSC) provide a useful tool for
regenerative medicine due to their differentiation cap-
acity, immunosuppressive properties, secretome profile
and migratory ability [1,2].
MSC represent a valuable source for research and clin-
ical applications due to their ability to produce a range of
different cell types including osteoblasts, adipocytes,* Correspondence: Alexandra.Stolzing@izi.fraunhofer.de
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Leipzig 04103, Germany
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reproduction in any medium, provided the orchondrocytes and myoblasts [3-6]. Effective cryopreserva-
tion MSCs offers an opportunity to advance the potential
use and implementation of these cells into clinical
applications.
Cryopreservation itself can affect differentiation capacity
of stem cells [7,8]. The loss of a variety of pluripotency
markers has been associated with cryopreservation [9,10]
but the precise reasons for these changes remain to be
explored.
Many studies on the cryopreservation of MSCs were
carried out using slow-rate cooling methods [11,12]l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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vation [13,14]. However, limited evidence exists whether
the freezing rate in fact affects stem cell growth and dif-
ferentiation potential. Both ‘slow’ [15-19] and ‘fast’
[20,21] freezing protocols have reported ‘success’ as far
as maintaining similar phenotypes, cell surface markers
and growth rates in comparison with unfrozen MSC.
Several groups have investigated MSC (from differ-
ent sources) cryopreservation using 10% DMSO and
slow freezing protocols. In these studies, the cryopre-
served MSC maintained similar phenotypes, cell sur-
face markers and growth rates in comparison with
fresh cells [19,22,23]. In addition fast freezing proto-
cols (vitrification) have been investigated with MSC,
showing normal proliferation, phenotype and differen-
tiation [20,21].
To facilitate freezing, a cryoprotectant is usually
added. An ideal cryoprotection solution should be non-
toxic for cells and patients, nonantigenic, chemically
inert, provide high survival rate after thawing and allow
transplantation without washing. The most commonly
used cryoprotector, DMSO, shows cytotoxicity [7,8].
Clinically, DMSO can cause leukoencephalopathy [24],
epileptic seizures [25] or elevated lactate dehydrogenase
levels [26] after transplantation of DMSO-preserved
human bone marrow cells. DMSO is thought to interact
with the metabolism and membrane of cells, resulting in
cell damage [27]. Nonetheless, DMSO is widely seen as
indispensible at least as a component of a cryoprotec-
tants solution.
Additions to DMSO include methycellulose [28], PVP
[29], trehalose [30] or others and these components are
not investigated here.
Another substitution compound for DMSO in
cryoprotection is Hydroxylethyl Starch (HES) which
is used in the clinical setting as a plasma volume ex-
pander [31-35]. A number of different cell types
have been cryopreserved using HES [36-38] with red
blood cells being routinely cryopreserved in cryopro-
tective solutions containing HES [33,39,40]. Bone
marrow cells from human and other animal species
have also been cryopreserved in HES-containing
solutions [41-43].
Physical and chemical properties such as solubility,
molecular stability as well as rate of hydrolysis and me-
tabolism depend on molecular weight (MW) and degree
of substitution of HES molecules. HESs with lower MW
have higher solubility and slower breakdown rates
[41,43]. A variety of different HESs with different MW
are currently clinically approved and commercially
available.
In this study we attempt an initial comparison of two
independent factors: freezing rates and cryopreservation
solutions. We analysed their effect on viability, growthcharacteristics and differentiation potential of rat MSCs
after cryopreservation.
Methods
Isolation of mesenchymal stem cells
The rat (Sprague Dawley, 2–3 month old, male) was
killed by controlled inhalation of CO2. The hind legs
were removed, the soft tissue removed and the separated
bones (tibia, femur) were stored in PBS. The bones were
centrifuged at 1000 rpm for 5 min and bone marrow
was resuspended in 1 ml DMEM.
Cell culture
Cells obtained from each animal were distributed into
two T75 flasks and incubated at 37°C. The first medium
change was done after 5 days and afterwards every 2 to
3 days. For the experiments we used MSCs from passage
1 to passage 3.
Rat MSCs were cultured in 1x Dulbecco’s modified
Eagle’s medium (DMEM, 1 g/L D-Glucose, Invitrogen)
containing 10% fetal bovine serum (FBS, Hyclone) and
1% penicillin/streptomycin (pen/strep, Invitrogen).
Cryopreservation
MSCs were frozen when they reached 80% confluency.
Prior to freezing, cell number was determined by trypan
blue staining using a Neubauer hemocytometer. 105 cells
were added to each cryogenic vial (2 ml Nalgene). MSC
were centrifuged for 5 min (1000 rpm at room
temperature) to pellet the cells, media was removed and
CPA was slowly (10 sec) added with a pipette and the
cells were carefully re-suspended. CPA were containing
500 μl of prepared cryoprotectant consisting of hydro-
xyethyl starches of different mean molecular weights
(MW=109, 209, 309, 409, 509, 609 kDa - Serumwerk,
Bernburg) and/or DMSO (Sigma-Aldrich)). Cryogenic
vials were kept on ice until samples were frozen applying
the different freezing protocols (Table 1) using a rate con-
trolled freezing system (Thermo Scientific) where indi-
cated Model 7452 Series). Protocols used on this study
were modified or newly designed based on published pro-
tocols [35,44-46]. The chamber of the freezing system
was pre-cooled to 4°C before each experiment. The sam-
ples were stored at −134°C in the vapor phase segment of
a liquid nitrogen tank for at least 24 h. Samples were
thawed at 37°C in a water bath and 104 cells were seeded
per well in triplicates into pre-warmed culture medium.
Fresh unfrozen MSC were seeded as a control.
MTT assay
The MTT assay was performed 3 days after thawing.
Each well was filled with 500 μl of media containing of
MTT-reagent, consisting of 5 mg/ml MTT (Carl Roth)
in PBS. After incubation for 4 h at 37°C, medium was
Table 1 Freezing protocols used
Protocol Description Duration [min] References
1 0,3°C/min to −100°C 347
Store in vapour phase at −134°C [47]*
2 1°C/min to −80°C 84 [46-50]
Store in vapour phase at −134°C
3 1°C/min to - 30°C 44
5°C/min to −80°C [44,51]*
xStore in vapour phase at −134°C
4 1°C/min to −20°C 34
5°C/min to −40°C
10°C/min to −80°C Designed
20°C/min to −100°C
Store in vapour phase at −134°C
5 1°C/min to −6°C 26
25°C/min to −50°C Designed
10°C/min to −90°C
Store in vapour phase at −134°C
6 Directly into the vapour phase 0
7 99°C/min to −100°C 2
Store in vapour phase at −134°C [35,52]*
* Modified.
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and 50% dimethylformamide, (VWR International)) was
added. The cells were incubated overnight at 37°C and ab-
sorbance was measured using a microplate reader
(TECAN) at 550 nm and 630 nm as reference wavelength.Osteogenic differentiation
The day after thawing medium was changed to osteoin-
ductive medium (low Glucose DMEM; 10% FBS; 1%
pen/strep; 10 nm dexamethasone, (Sigma-Aldrich);
50 μg/ml ascorbic acid 2-phosphate, (Sigma-Aldrich)).
Differentiation media was changed every 2 days for a
period of 14 days. For qualitative analysis of osteogenic
differentiation, cells were fixed in 70% ethanol for
15 min and washed once with ddH2O.
After washing, cells were stained with ALP buffer pH
8.5 (0.2 M Tris, 1 mg/ml fast red, Sigma and 50 μg/ml
naphtol phosphate AS-BI, Sigma) for 1 hr.Adipogenic differentiation
Adipogenic medium (10% FBS; 1% pen/strep, 10%
insulin-transferrin-selenium supplement, (Sigma-Aldrich)
10-8 M dexamethasone (Sigma-Aldrich); 0.5 mM isobutyl-
methylxanthine, Sigma-Aldrich; 100 μM indomethacin,
Sigma-Aldrich) was added the day after thawing. The
media was changed every 2 days. After 14 days cell pheno-
type was analyzed by Oil Red O (Sigma-Aldrich) staining.Chondrogenic differentiation
Chondrogenic media (10% FBS; 1% pen/strep 1% insulin-
transferrin-selenium supplement (Sigma-Aldrich), 10-7 M
dexamethasone (Sigma-Aldrich), 150 μM ascorbic-2-
phosphate (Sigma-Aldrich), 20 μM linoic acid (Sigma-
Aldrich) and 0.1 ng/ml TGF-β (Oncogenic Sciences) was
added after thawing. After 2 weeks, cells were stained with
Alcian Blue (Sigma-Aldrich).Quantitative alkaline phosphatase (ALP) assay
After 14 days of differentiation, the 24 well-plates were
washed and fixed with ice-cold 70% ethanol for 20 min.
Ethanol was removed, the plates washed and incubated
with 1 ml of p-nitrophenylphosphate (1 mg/ml, Calbio-
chem) in TRIS (pH 8.0). Cells were incubated for 1 h at
RT and absorbance measured at 405 nm using a micro-
plate reader (TECAN). Subsequently, the 24 well-plates
were rinsed with ddH2O and washed with 10 mm borate
buffer (pH 8.5, Sigma-Aldrich). 500 μl methylene blue
(1 mg/ml, Sigma-Aldrich) in 10 mm borate buffer was
added to each well. After 30 min incubation at RT the
plates were washed with 10 mm borate buffer and
500 μl 1% hydrochloric acid (VWR International) was
used for dye elution. Plates were incubated for 30 min at
RT and absorbance was measured at 650 nm using a
microplate reader (TECAN).Phenotyping of mesenchymal stem cells
Cells were incubated with CD90 (1:50, Abcam), CD45
(1:100, AbD Serotec), CD11b (1:100, Abcam), and CD44
(1:50, Millipore) for 1 h at 4°C, washed and incubated
with Cy2 (1:750, Jackson ImmunoResearch) for 45 min
at 4°C. Cells were washed again and analyzed using the
Cytomics FC500 flow cytometer and CXP Analysis 2.1
software (Beckman Coulter).Cell morphology
Morphology of the cells was analyzed 3 days after thaw-
ing by light microscopy. Pictures were taken at 10x
magnification.Statistics
All experiments were repeated at least three times. Stat-
istical analysis was performed using ANOVA followed
by Turkey test, with p < 0.05 considered an indicator of
robustness (although not of absolute statistical signifi-
cance as the number of experiments was too low).Results
Rat MSCs were cryopreserved in vials using seven differ-
ent freezing protocols (Table 1). Different concentrations
of DMSO and HES alone or in mixture were tested.
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Some studies (in the 80's) [53,54] have stressed the im-
portance of capturing a consistent ice nucleation point.
While in our experiments (in keeping with many
machine-based freezing practices in tissue engineering)
nucleation was not initiated ‘manually’, we can show that
nucleation occurs consistently as indicated by a character-
istic [55] ‘heat release’ spike (Additional file 1 Figure S4).
Post-thaw phenotyping
CD90, CD44, CD45 and CD11b expression were mea-
sured in samples cryopreserved using protocol 1 and 7,
in 90% DMEM and three different cryosolutions: 10%
DMSO, 10% HES 450 and 5% DMSO/5% HES 450. CDs
were measured directly after thawing and 3 days later
and compared to non-cryopreserved cells (Figure 1).
As expected, both MSCs after cryopreservation and
non-cryopreserved MSCs have low expression of
hematopoietic stem cell markers CD45 and CD11b
and high expression of mesenchymal-associated marker
CD90 and CD44 [21,56,57]. No differences in CDFigure 1 MSC phenotyping. Level of CD-expression in MSCs cryopreserve
with protocol 1 (A) and protocol 7 (B).expression were observed between day 0 and 3 in both
protocols. Usage of HES 450 and DMEM results in
low cell number after 3 days therefore no CD pheno-
typing was performed.
Post-thaw viability
Directly after thawing, we recorded approximately 85%
cell viability with no observed difference between
the different protocols and cryoprotectant-solutions
(Figure 2A-B). However, viability of cells directly after
thawing cannot represent reliable criteria for estimation
of cryopreservation efficacy. After cultivation for 3 days,
a considerable decrease in viability for some solutions
was observed (Figure 2C-D). This post-thaw decrease in
cell viability is known to be related to apoptotic and nec-
rotic processes which occur within first 24 hours and are
not evident immediately after thawing [16,58,59]. On
day 3 after thawing, DMSO concentrations under 4% are
associated with reduced MSC viability (Figure 2D). The
solution of 8% DMSO / 2% HES 450 shows on average
of all protocols the highest viability compared to alld in different solutions directly after thawing (day 0) and after 3 days
Figure 2 The effect of cryopreservation on MSC viability immediately after thawing and after 3 days at various HES/DMSO
combinations and freezing rates. Viability of MSCs after cryopreservation with either different freezing rates (A, C) or different concentrations of
DMSO and HES 450 (B,D) measured directly after thawing (A, B) and after 3 days by MTT (C, D).
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alone (10% HES 450) is associated with low cell viability.
MSC viability was maintained at 14 days (Figure 3B)
showing that proliferation activity is not affected by pro-
longed culture (Additional file 2 Figure S2).
HES with the same molar substitution (0.7) but differ-
ent molecular weight distributions were investigated in
order to determine the relation between size of HES and
its cryoprotective capacity. We used the cooling proto-
cols 1, 5, and 6 (Table 1) which were chosen as the pro-
tocols with the most different parameters. No difference
in cell viability at day 0 was observed between the solu-
tions and protocols (data not shown). HES solutions in
DMEM and FCS showed less cell viability at day 3 post-
thawed compared to DMSO controls (Figure 4A).
As a trend, higher HES molecular weight seems to
sustain cell viability (with notable exception for protocol
5) but only in FCS not in DMEM (Figure 4A and B).
Post-thaw differentiation capacity
Thawed MSC retain their capacity to differentiate to-
ward osteoblasts, adipocytes and chondrocytes. Quali-
tative assessment of the osteogenic, adipogenic and
chondrogenic differentiation of MSC shows no differ-
ence in effect between the different cryosolutions
(Additional file 3 Figure S1), but we only pursued
osteogenic capacity in greater detail.ALP activity is lower at ‘high’ (>5%) levels of DMSO
compared to solutions with a higher HES 450 content
(Figure 3, C and Additional file 4 Figure S3).
No differences could be observed between HES of dif-
ferent molecular weights and there was no effect attrib-
utable to concurrent use of either serum or DMEM
(Figure 4c).Post-thaw phenotyping
CD90, CD44, CD45 and CD11b expression were mea-
sured in samples cryopreserved using protocol 3 and 6,
in three different cryosolutions: 10% DMSO+medium,
10% HES 450 +medium and 5% DMSO/5% HES
450 +medium. CDs were measured directly after thaw-
ing and 3 days later and compared to non-cryopreserved
MSC (Figure 1).
As expected, both MSCs after cryopreservation and non-
cryopreserved MSCs have low expression of hematopoietic
stem cell markers CD11b and CD45 and high expression of
mesenchymal-associated marker CD90 and CD44 [56,57].
No differences in CD expression were observed between
day 0 and 3 in both protocols. Cryopreservation did lead to
a further reduction of hematopoetic makers CD11b and
CD45. Usage of HES 450 and DMEM results in such low
cell number after 3 days that no CD phenotyping was
possible.
Figure 3 Cryopreservation of MSCs using HES/DMSO combinations. Viability of MSCs after cryopreservation with different concentrations of
DMSO and HES 450, measured by 3 days after thawing in normal media (A) and after 14 days of osteogenic differentiation (B). Alkaline
phosphatase activity of cryopreserved MSCs after osteogenic differentiation for 14 days (C).
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It is not uncommon to analyze cell viability directly after
thawing [47,48,60-62], however our results clearly show
that this is an inaccurate measure of cryopreservation
effects in rat MSC, since the different effects of various
cryosolutions tested were only observable 3 days after
thawing and beyond. Cryopreservation associated cell
death is known to occur from 6 h after thawing and be-
yond [63-66]. We investigated different cooling proto-
cols and found a constant cooling rate of 1°C per min
until −30°C followed by 5°C per min until −80°C and
protocols with a fast cooling rate (protocols 1 & 6) are
equally suitable considering cell viability and recovery in
the cryopreservation of rat MSCs. However, the choice
of protocol seems to have a rather marginal effect on
post-thaw viability, with little difference to a ‘straight
freeze’ approach (protocols 6) that saves considerable
time and effort. Survival rates were in the range ofprevious reports and MSC phenotypes were not affected
by cryopreservation. It could be argued that protocols
1–3 are essential ‘the same’ with regards to the pre-
cooling rate of hypothetical importance, i.e., the one that
governs the biophysical response of the cells being
cooled. Indeed, we observe no difference between these
protocols. However, since the different protocols are in
practical use we have maintained their differentiated
profile for reference.
DMSO reduction using alternative cryoprotectants
As discussed above and previously [43], the use of
DMSO has several disadvantages. However, based on
these results in rat MSC, a total substitution of DMSO
with HES is not advisable if cell viability is a key indica-
tor. Upon reducing DMSO concentration below 4% an
observed decrease in cell viability can be measured,
probably because of ice crystal growth in the relatively
Figure 4 Effect of HES with different molecular weight distributions on MSCs cryopreservation. Viability of MSCs after cryopreservation
with 10% HES of different molecular weight distributions (109–609) in combination with DMEM or FCS, measured 3 days after thawing (A) and by
methylene blue staining after osteogenic differentiation for 14 days (B). Alkaline phosphatase activity of cryopreserved MSCs after osteogenic
differentiation for 14 days (C).
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change of water against DMSO during the relatively
short incubation time of the cells in DMSO.
However, we could observe a slight reduction of osteo-
genic capacity related to higher DMSO concentrations.
It is known that oxidative stress induces differentiation
[67], which also occurs during freezing [68]. A badly
designed freezing protocol might induce differentiation
impacting on the quality of the stem cells.
If these or other drawbacks of DMSO are a factor, our
results show that a partial replacement of DMSO with
HES is certainly possible. Studies using a 6% HES + 5%
DMSO solution usually show superior cryopreservation
in comparison to 10% DMSO [43]. Regarding the
‘optimum’ between MSC survival and osteogenic differ-
entiation one can conclude that while lowest DMSO
concentration are slightly better for differentiation for
practical tissue engineering purposes a DMSO concen-
tration of 5% or slightly higher should be preferable.Molecular weight of HES
In previous cryopreservation studies different MW of
HES ranging from 150 to 450 kDa were used but not
compared, making it difficult to know if there are differ-
ences between the variable HES solutions [33,69]
For the first time we compared the effects of HES ran-
ging from 109 to 609 kDa with a similar hydroxyl substi-
tution rate on viability and osteogenic differentiation.
The cryopreservation with HES of different molecular
weights had no effect on survival and differentiation of
MSCs.
Conclusion
1. The study confirms that, for rat MSC,
cryopreservation effects need to be assessed some
time after, rather than immediately after thawing.
2. MSCs cryopreserved with HES maintain their
characteristic cell surface marker expression as well
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differentiation potential.
3. There are no major changes in the expression of
surface proteins identifying MSC, proliferation
capacity and osteogenic differentiation in MSC
frozen with 5% DMSO/ 5% HES.
4. HES alone does not provide sufficient
cryoprotection for rat MSCs, but provides good
cryoprotection in combination with DMSO,
permitting the DMSO content to be reduced to 5%.
There are indications that such a combination
would seem useful not just for the clinical
disadvantages of DMSO but also based on a
tendency for reduced osteogenic differentiation
capacity in rat MSC cryopreserved with high DMSO
concentration.
5. HES molecular weight appears to play only a minor
role in its capacity to act as a cryopreservation
solution for MSC.
6. The use of a ‘straight freeze’ protocol is no less
effective in maintaining post-thaw viability of MSC
compared to controlled rate freezing methods.
As a simplified summary, a 5% DMSO / 5% HES solu-
tion cryopreservation solution using a ‘straight freeze’
approach can be recommended as ‘optimal’ for ‘normal’
rat MSC cryopreservation.Additional file
Additional file 1: Figure S4. Freezing curves of the machine
cryopreservation protocols. The curves for the machine based freezing
rates were recorded by the machine and summarized here for the
protocols 1–6. The curves show just small variations during the heat
release phase between 0 and −10°C.
Additional file 2: Figure S2. Cellular Morphology of cryopreserved rat
MSC. Morphology of cryopreserved rat MSC after 14 days in culture.
Additional file 3: Figure S1. Differentiation capacity of rat MSCs after
cryopreservation. Qualitative ALP-staining of MSCs after 14 days
osteogenic differentiation. Magnification 20X (A). Oil red O staining of
MSCs after 14 days in adipogenic differentiation medium. Magnification
40X (B). Chondrogenic staining of differentiated MSCs cells after 14 days.
Magnification 20X (C).
Additional file 4: Figure S3. Morphology of cryopreserved rat MSC
during osteogenesis. Cellular morphology of cryopreserved rat MSC after
14 days in osteogenic differentiation medium.Competing interests
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